ArticleCommunications biology2025
MIF downregulation attenuates neuroinflammation via TLR4/MyD88/TRAF6/NF-κB pathway to protect dopaminergic neurons in Parkinson's disease model.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Macrophage Migration Inhibitory Factor Inhibitor ISO-1 Attenuates Anesthesia/Surgery-Induced Cognitive Impairment in Aged Mice: Association with NLRP3 Inflammasome Inhibition.Neurochemical research · 2026Article
- Research advances on acute kidney injury and brain dysfunction.Frontiers in nephrology · 2026Review
- Article
- Neuronal exosomal miR-25-3p attenuates M1 microglial activation and neurotoxicity by targeting TLR4 to regulate the NF-κB signaling pathway.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The progression of Parkinson's disease (PD) is closely associated with neuroinflammatory responses and microglial activation. Consequently, research targeting microglia-mediated neuroinflammation has garnered increasing attention. Macrophage migration inhibitory factor (MIF), a multifunctional cytokine, is implicated in neurodegenerative pathologies, including PD. However, its precise regulatory mechanisms in PD-associated microglial activation and neuroinflammatory cascades remain incompletely characterized. In this study, we observe that MIF exacerbates the pathogenesis of PD through its pro-inflammatory effect, and downregulation of MIF could ameliorate motor behavior deficits, attenuate neuroinflammation, and protect midbrain dopamine (DA) neurons in PD mice. Mechanistically, MIF downregulation attenuates neuroinflammation and exerts neuroprotection against microglia-induced neuronal injury and degeneration by regulating the TLR4/MyD88/TRAF6 signaling axis. In conclusion, this study elucidates the pivotal role of MIF in regulating neuroinflammation associated with PD, suggesting that MIF may be a potential therapeutic target for intervening in PD progression, and providing new strategies for PD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.